<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate
Contact Us
Contact Us

inline monitoring QA download graphic32

 

Downstream strategies for concentration and purification of Lentiviral Vectors from suspension cell-based systems

Overview

Lentiviral vectors (LVV), produced with transient quadri-transfection in 293T cell line, are extensively used for genetic modification in gene therapy, and have already shown great promise, with several clinical trials demonstrating their efficacy in treating diseases. The demand for LVV is constantly rising to support advanced clinical phases and commercial applications. In this scientific poster, presented at Advanced Therapies Week 2024, we offer an overview of the different strategies that can be used to successfully create a downstream process for the concentration and purification of lentiviral vectors from suspension cell-based systems.

AGCellerate logo RGB

Accelerate your LVV production timeline!

A minimum of 1e11 total TU LVV product​ in 9 months!

AGCellerate™ for LVV provides a fixed price, timeline, and quantity to support your vector project's clinical goals, offering developers - particularly those focused on rare diseases - a standardized platform process.

 

Accelerate your project